DK174976B1 - Farmaceutiske sammensætning og fremgangsmåde til stabilisering af et ACE inhibitormedikament - Google Patents
Farmaceutiske sammensætning og fremgangsmåde til stabilisering af et ACE inhibitormedikament Download PDFInfo
- Publication number
- DK174976B1 DK174976B1 DK198705436A DK543687A DK174976B1 DK 174976 B1 DK174976 B1 DK 174976B1 DK 198705436 A DK198705436 A DK 198705436A DK 543687 A DK543687 A DK 543687A DK 174976 B1 DK174976 B1 DK 174976B1
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- ascorbic acid
- drug
- weight
- lubricant
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title claims abstract description 14
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 30
- 229940079593 drug Drugs 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 12
- 230000000087 stabilizing effect Effects 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 230000007062 hydrolysis Effects 0.000 claims abstract description 16
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 16
- 239000000314 lubricant Substances 0.000 claims abstract description 16
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 16
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 36
- 229960005070 ascorbic acid Drugs 0.000 claims description 27
- 235000010323 ascorbic acid Nutrition 0.000 claims description 27
- 239000011668 ascorbic acid Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 19
- 229960001455 quinapril Drugs 0.000 claims description 15
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000000454 talc Substances 0.000 claims description 7
- 229910052623 talc Inorganic materials 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 15
- 239000002253 acid Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010061435 Enalapril Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 229960000873 enalapril Drugs 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XYGSFNHCFFAJPO-UHFFFAOYSA-N Chlophedianol hydrochloride Chemical compound Cl.C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 XYGSFNHCFFAJPO-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940020114 chlophedianol hydrochloride Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- 229960002254 phenyltoloxamine citrate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 229940018203 pyrilamine maleate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Lubricants (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92193186 | 1986-10-20 | ||
| US06/921,931 US4793998A (en) | 1986-10-20 | 1986-10-20 | Stabilized drug compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK543687D0 DK543687D0 (da) | 1987-10-16 |
| DK543687A DK543687A (da) | 1988-04-21 |
| DK174976B1 true DK174976B1 (da) | 2004-04-05 |
Family
ID=25446206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198705436A DK174976B1 (da) | 1986-10-20 | 1987-10-16 | Farmaceutiske sammensætning og fremgangsmåde til stabilisering af et ACE inhibitormedikament |
Country Status (19)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1322957C (en) * | 1988-03-30 | 1993-10-12 | Hitoshi Yamauchi | Cyclic amp derivative ointments |
| US5006344A (en) * | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
| CA2019324C (en) * | 1989-07-10 | 1996-08-20 | Robert L. Jerzewski | Fosinopril tablet formulations |
| JP3210663B2 (ja) * | 1990-04-06 | 2001-09-17 | エーザイ株式会社 | カテコール化合物を含有する経口用固形製剤 |
| HU222489B1 (hu) * | 1990-07-25 | 2003-07-28 | Novartis Ag. | Stabilizált gyógyszerkészítmények és eljárás az előállításukra |
| US6300362B1 (en) | 1990-07-25 | 2001-10-09 | Novartis Ag (Formerly Sandoz Ltd.) | Stabilized pharmaceutical compositions comprising acid donors |
| HU222497B1 (hu) * | 1996-12-18 | 2003-07-28 | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. | Enalapril-maleátot tartalmazó stabilizált gyógyszerkészítmény és eljárás előállítására |
| US6296871B1 (en) * | 1998-04-12 | 2001-10-02 | Ranbaxy Laboratories Limited | Stable solid pharmaceutical compositions containing enalapril maleate |
| EP1083931B1 (en) * | 1998-06-05 | 2005-05-11 | Warner-Lambert Company LLC | Stabilization of compositions containing ace inhibitors using magnesium oxide |
| US20030225124A1 (en) * | 1999-08-31 | 2003-12-04 | Spiridon Spireas | Stable formulations of ACE inhibitors, and methods for preparation thereof |
| US6555551B1 (en) | 1999-08-31 | 2003-04-29 | Mutual Pharmaceutical Co., Inc. | Stable formulations of ACE inhibitors, and methods for preparation thereof |
| US20040157911A1 (en) * | 1999-08-31 | 2004-08-12 | Spiridon Spireas | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
| AU7580000A (en) * | 1999-09-17 | 2001-04-17 | Mylan Pharmaceuticals, Inc. | Stabilization of enalapril maleate with maleic acid |
| EP1457207A4 (en) * | 2001-12-19 | 2008-05-28 | Takeda Pharmaceutical | SOLID COMPOSITIONS WITH OXYGEN INSTABILITY COMPOUNDS AND STABILIZATION METHOD THEREFOR |
| BR0306928A (pt) * | 2002-01-15 | 2004-11-09 | Ranbaxy Lab Ltd | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) |
| US20050069586A1 (en) * | 2003-06-26 | 2005-03-31 | Julia Hrakovsky | Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives |
| US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
| GR1006875B (el) * | 2005-06-30 | 2010-07-12 | "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., | Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων. |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
| CA2647705A1 (en) * | 2006-04-19 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| US20080008694A1 (en) | 2006-07-05 | 2008-01-10 | Elgebaly Salwa A | Methods to prevent and treat diseases |
| ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
| JP2022135147A (ja) * | 2021-03-04 | 2022-09-15 | 日医工株式会社 | サキサグリプチン含有錠剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (enrdf_load_stackoverflow) * | 1957-07-17 | |||
| US3697641A (en) * | 1970-01-02 | 1972-10-10 | Gerhard W Ahrens | Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate |
| EP0045238B1 (en) * | 1980-07-29 | 1986-10-01 | Sanofi S.A. | Acid stabilized compositions of thieno-pyridine derived compounds and process for preventing degradation of such compounds |
| US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4442089A (en) * | 1982-07-06 | 1984-04-10 | E. R. Squibb & Sons, Inc. | Method for treating glaucoma with topical or systemic ACE inhibitor compositions |
| US4499079A (en) * | 1982-11-18 | 1985-02-12 | E. R. Squibb & Sons, Inc. | Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides |
| US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4656188A (en) * | 1985-10-09 | 1987-04-07 | Merck & Co., Inc. | Ace inhibitors in macular degeneration |
-
1986
- 1986-10-20 US US06/921,931 patent/US4793998A/en not_active Expired - Lifetime
-
1987
- 1987-09-18 CA CA000547230A patent/CA1297023C/en not_active Expired - Lifetime
- 1987-09-22 IE IE254987A patent/IE61436B1/en not_active IP Right Cessation
- 1987-09-22 ZA ZA877131A patent/ZA877131B/xx unknown
- 1987-10-01 AU AU79274/87A patent/AU614710B2/en not_active Expired
- 1987-10-16 DK DK198705436A patent/DK174976B1/da not_active IP Right Cessation
- 1987-10-19 AT AT87115282T patent/ATE65915T1/de not_active IP Right Cessation
- 1987-10-19 FI FI874593A patent/FI94092C/fi not_active IP Right Cessation
- 1987-10-19 EP EP87115282A patent/EP0264888B1/en not_active Expired - Lifetime
- 1987-10-19 JP JP62261930A patent/JP2852043B2/ja not_active Expired - Lifetime
- 1987-10-19 ES ES198787115282T patent/ES2040231T3/es not_active Expired - Lifetime
- 1987-10-19 PT PT85941A patent/PT85941B/pt unknown
- 1987-10-19 DE DE8787115282T patent/DE3772001D1/de not_active Expired - Lifetime
- 1987-10-19 NO NO874351A patent/NO174765C/no not_active IP Right Cessation
- 1987-10-20 KR KR1019870011655A patent/KR960000431B1/ko not_active Expired - Fee Related
- 1987-10-20 PH PH35961A patent/PH25502A/en unknown
-
1991
- 1991-08-08 GR GR91401122T patent/GR3002454T3/el unknown
-
1994
- 1994-07-07 SG SG90194A patent/SG90194G/en unknown
- 1994-08-18 HK HK85394A patent/HK85394A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT85941A (en) | 1987-11-01 |
| IE872549L (en) | 1988-04-20 |
| JP2852043B2 (ja) | 1999-01-27 |
| FI94092C (fi) | 1995-07-25 |
| PT85941B (pt) | 1990-07-31 |
| CA1297023C (en) | 1992-03-10 |
| SG90194G (en) | 1994-10-14 |
| FI874593A0 (fi) | 1987-10-19 |
| ES2040231T3 (es) | 1993-10-16 |
| NO874351D0 (no) | 1987-10-19 |
| PH25502A (enrdf_load_stackoverflow) | 1991-07-24 |
| ZA877131B (en) | 1989-04-26 |
| US4793998A (en) | 1988-12-27 |
| EP0264888A1 (en) | 1988-04-27 |
| DK543687A (da) | 1988-04-21 |
| JPS63104930A (ja) | 1988-05-10 |
| FI874593L (fi) | 1988-04-21 |
| AU7927487A (en) | 1988-04-28 |
| HK85394A (en) | 1994-08-26 |
| DE3772001D1 (de) | 1991-09-12 |
| ATE65915T1 (de) | 1991-08-15 |
| NO174765C (no) | 1994-07-06 |
| DK543687D0 (da) | 1987-10-16 |
| GR3002454T3 (en) | 1992-12-30 |
| IE61436B1 (en) | 1994-11-02 |
| AU614710B2 (en) | 1991-09-05 |
| EP0264888B1 (en) | 1991-08-07 |
| KR960000431B1 (ko) | 1996-01-06 |
| NO174765B (no) | 1994-03-28 |
| NO874351L (no) | 1988-04-21 |
| KR880004812A (ko) | 1988-06-27 |
| FI94092B (fi) | 1995-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK174976B1 (da) | Farmaceutiske sammensætning og fremgangsmåde til stabilisering af et ACE inhibitormedikament | |
| DK174916B1 (da) | Farmaceutisk sammensætning og fremgangsmåde til at stabilisere denne | |
| DK169593B1 (da) | Farmaceutiske præparater med forbedret stabilitet samt fremgangsmåde til stabilisering af et ACE-inhibitor lægemiddel | |
| AU2004208617A2 (en) | Stable solid medicinal composition for oral administration | |
| US4859665A (en) | Antihypertensive combination products containing a dihydropyridine and a pyridazodiazepine | |
| CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| JPH03215426A (ja) | 血糖上昇抑制剤 | |
| US4918076A (en) | Treating alcohol addiction with 1,4-dihydropyridine derivatives | |
| IE71022B1 (en) | Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamides containing preparation and stabilizing method therefor | |
| EP0024868A1 (en) | Schistosomicidal composition comprising oxamniquine and praziquantel | |
| AU2978500A (en) | Method for the prevention or reduction of cardiovascular events associated with coronary intervention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |